Nuplazid

3 Biotech Stocks That Soared Last Week
3 Biotech Stocks That Soared Last Week
Motley Fool
Acadia Pharmaceuticals
Nuplazid
Mesoblast
Grunenthal
MPC-06-ID
Kodiak Sciences
age-related macular degeneration
Flag link:
Acadia calls early halt to Nuplazid psychosis trial after promising interim results
Acadia calls early halt to Nuplazid psychosis trial after promising interim results
Fierce Pharma
Acadia Pharmaceuticals
Nuplazid
dementia-related psychosis
Flag link:
Trial win could drive Acadia's Nuplazid to new use
Trial win could drive Acadia's Nuplazid to new use
Biopharma Dive
Acadia Pharmaceuticals
Nuplazid
dementia-related psychosis
clinical trials
FDA
Flag link:
Acadia drops after hours on Phase III miss for schizophrenia
Acadia drops after hours on Phase III miss for schizophrenia
BioCentury
Acadia
Nuplazid
schizophrenia
clinical trials
Flag link:
Upcoming events – Acadia hopes for new indications for Nuplazid
Upcoming events – Acadia hopes for new indications for Nuplazid
EP Vantage
Acadia Pharmaceuticals
antipsychotics
Nuplazid
schizophrenia
dementia
Flag link:
Justice Department launches probe into Acadia's Nuplazid marketing
Justice Department launches probe into Acadia's Nuplazid marketing
Fierce Pharma
Acadia Pharmaceuticals
Nuplazid
DOJ
drug marketing
Flag link:
Acadia Pharma Soars After FDA Investigation Clears Nuplazid of Additional Safety Problems
Acadia Pharma Soars After FDA Investigation Clears Nuplazid of Additional Safety Problems
BioSpace
Acadia
FDA
Nuplazid
Parkinson's Disease Psychosis
Flag link:
Under Fire for Risk/Efficacy Profile – Nuplazid Shows Potential for Treating Dementia-Related Psychosis
Under Fire for Risk/Efficacy Profile – Nuplazid Shows Potential for Treating Dementia-Related Psychosis
CP Wire
Acadia
Nuplazid
pimavanserin
dementia-related psychosis
Parkinson's Disease Psychosis
Flag link:
Under Fire for Risk/Efficacy Profile – Nuplazid Shows Potential for Treating Dementia-Related Psychosis
Acadia
Nuplazid
pimavanserin
dementia-related psychosis
Flag link:
Acadia can’t shake off its Nuplazid nightmare
Acadia can’t shake off its Nuplazid nightmare
EP Vantage
Acadia
FDA
Nuplazid
antipsychotic
Flag link:
FDA re-examines safety of controversial new drug Nuplazid
FDA re-examines safety of controversial new drug Nuplazid
CNN
FDA
Nuplazid
congress
Parkinson's Disease
Acadia
Flag link:
CNN Article Details Deaths and Other Adverse Events Linked to Acadia's Nuplazid
CNN Article Details Deaths and Other Adverse Events Linked to Acadia's Nuplazid
CP Wire
Acadia
Nuplazid
Parkinson's Disease Psychosis
Flag link:
CNN Article Details Deaths and Other Adverse Events Linked to Acadia's Nuplazid
Acadia
Nuplazid
Parkinson's Disease Psychosis
Flag link:
These 2 Biotechs Could Vanish by 2018
These 2 Biotechs Could Vanish by 2018
Motley Fool
biotech
Acadia
MannKind
Nuplazid
Afrezza
Flag link:
10 Must-Know Biotech Stock Events to Close Out 2016
10 Must-Know Biotech Stock Events to Close Out 2016
TheStreet.com
biotech
Eli Lilly
solanezumab
Biogen
aducanumab
Kite Pharma
KTE-C19
Bluebird Bio
LentiGlobin
Sarepta Therapeutics
eteplirsen
Ophthotech
Fovista
Bristol-Myers Squibb
Opdvio
Acadia
Nuplazid
Celgene
GED-301
Gilead Sciences
M&A
Flag link:
3 Biotech Stocks With Explosive Upside Potential
3 Biotech Stocks With Explosive Upside Potential
Motley Fool
Acadia
Nuplazid
Radius Health
abaloparatide-SC
Sarepta Therapeutics
eteplirsen
Flag link:
U.S. approves first drug for psychosis linked to Parkinson's
U.S. approves first drug for psychosis linked to Parkinson's
Yahoo/Reuters
Parkinson's Disease Psychosis
FDA
Acadia
Nuplazid
Flag link:
Why Biogen Should Acquire ACADIA Pharmaceuticals
Why Biogen Should Acquire ACADIA Pharmaceuticals
Bidness, ETC
Biogen
Acadia
M&A
Parkinson's Disease Psychosis
Nuplazid
Flag link:
It could reduce hallucinations, but at what cost? New Parkinson’s drug raises questions
It could reduce hallucinations, but at what cost? New Parkinson’s drug raises questions
Stat
Parkinson's Disease Psychosis
Nuplazid
Acadia
Flag link:
FDA's internal review of Acadia's Parkinson's drug raises safety, benefit concerns
FDA's internal review of Acadia's Parkinson's drug raises safety, benefit concerns
Fierce Biotech
FDA
Acadia
Parkinson's Disease Psychosis
Nuplazid
Flag link:

Pages